Skip to main content

Table 1 Characteristics of included studies

From: Prognostic value of mid-regional pro-adrenomedullin (MR-proADM) in patients with community-acquired pneumonia: a systematic review and meta-analysis

Author Year Country Study design Clinical setting Endpoint Sample size (n) Male (%) Age CURB65 % (2–5) PSI % (IV–V) Prevalence of mortality (%) Cut-off (nmol/L) TP FP FN TN Sen (95 % CI) Spe (95 % CI)
Albrich [27] 2011 Switzerland MRCT + CR ED 30 day mortality 925 - - 53.8 NA 5.41 1.5 36 295 14 580 72 66.3
      Adverse events       14.5 0.75 256 475 11 183 95.9 27.8
Bello [28] 2012 Spain PR + CR ED 30 day mortality 224 61 73 (63–80) 59.2 61 5.8 1.066 12 68 1 143 92.3 67.46
      Complications       64 0.833 98 26 48 52 67.35 66.23
Christ-Crain [29] 2006 Switzerland PR + CR ED 6.9 ± 1.9 weeks 302 61.9 69.6 ± 17.0 - 60.2 12.6 1.8 30 74 8 190 80 72
Courtais [30] 2013 France PR + CR ED 30 day mortality 109 65.1 71.1 (53–84) - 56 8.26 1.8 7 25 2 75 77.8 75
Huang [31] 2009 America MPR ED 30 day mortality 1653 52 65.0 ± 18.5 - 39 6.4 1.3 72 418 34 1129 68 73
Kolditz [32] 2012 Germany PR + CR ED ICU admission or 7 day mortality 51 49 72 (41–80) - - 17.6 1.05 6 6 3 36 67 85
Kruger [33] 2009 Germany RCT + CR ED 28 day mortality 728 59.1 59 ± 18.2 - - 2.5 0.959 14 168 4 542 77.8 76.3
Julian-Jimenez [34] 2014 Spain PR + CR ED 30 day mortality 127 74 65.8 ± 20.02 55.9 55.1 10.3 1.85 11 21 2 93 84.6 81.4
Suberviola [35] 2012 Spain PR ICU In-hospital mortality 49 67.3 59.4 ± 13.4 - - 35 4.86 9 5 8 27 53 84
Lacoma [36] 2014 Spain PR HW Complications 85 69.4 - 48.2 61.2 10.6 1.5 6 26 3 50 66.7 65.8
Bereciartua Urbieta [37] 2011 Spain PR ED Unfavorable outcome 250 31.6 71.1 - - 33.2 1.2 66 78 17 89 80 53
Renaud [38] 2012 America/Spain/France MRCT + CR ICU SCAP 877 58.8 73 (59–83) - - 5.6 1.8 49 184 31 613 61.3 76.9
  1. SCAP severe community-acquired pneumonia, ICU intensive care unit, ED emergency department, HW hospital ward, PR prospective recruitment, CR consecutive recruitment, RR retrospective recruitment, RCT randomized controlled trial, MPR multi-center prospective recruitment, MRCT multi-center random controlled trial, TP true positive, FP false positive, TN true negative, FN false negative, SEN sensitivity, SPE specificity, CI confidence interval